Semiconductor Biochip Market size was valued at US$ 1.89 billion in 2024 and is projected to reach US$ 6.78 billion by 2032, at a CAGR of 20.3% during the forecast period 2025-2032
help@semiconductorinsight.com
Report Studies
• The global Semiconductor Biochip Market size was valued at US$ 1.89 billion in 2024 and is projected to reach US$ 6.78 billion by 2032, at a CAGR of 20.3% during the forecast period 2025-2032. This growth aligns with broader semiconductor industry trends, where the global market was estimated at USD 579 billion in 2022 and is expected to expand to USD 790 billion by 2029 at a 6% CAGR.
• Semiconductor biochips are miniaturized devices that integrate biological components with electronic circuits to enable high-throughput analysis. These chips are categorized into active chips (with integrated sensors/processors) and passive chips (for sample handling). They find applications across medical diagnostics, life sciences research, pharmaceutical development, and agricultural biotechnology. The technology enables parallel processing of thousands of biological reactions simultaneously, dramatically accelerating research workflows.
By Type:
• The market is segmented based on type into:
• Active chips
• Subtypes: Microarrays, lab-on-achip, biosensors
• Passive chips
• Subtypes: DNA chips, protein chips, cell chips
By Application:
• The market is segmented based on application into:
• Medical diagnostics
• Life science research
• Pharmaceutical development
• Agricultural biotechnology
• Others
Key Players:
• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific (U.S.)
• Cellix Ltd. (Ireland)
• GE Healthcare (U.K.)
• Randox Laboratories (U.K.)
• BioDot, Inc. (U.S.)
• PerkinElmer (U.S.)
• Roche Diagnostics (Switzerland)
• Horiba (Japan)
• Greiner Bio-One International (Austria)
